CTGTAC meeting scheduled for Replimune's BLA 125827
- Sponsor
- Replimune, Inc. $REPL
- Drug
- vusolimogene oderparepvec
FDA schedules Cellular, Tissue, and Gene Therapies Advisory Committee meeting to discuss Replimune's BLA 125827 for vusolimogene oderparepvec.
What this means
Vusolimogene oderparepvec is an experimental cancer treatment that uses a modified virus to attack tumors while stimulating the immune system. The FDA scheduled an advisory committee meeting to review Replimune's application for the therapy, with experts set to evaluate its risks and benefits. This meeting could influence whether the treatment becomes available for patients with certain advanced cancers who lack other options.
From the source
Request Access
Due to aggressive automated scraping of FederalRegister.gov and eCFR.gov, programmatic access to these sites is limited to access to our extensive developer APIs. Please visit
FederalRegister.gov API
documentation or
eCFR.gov API
documentation to learn more about how to access the API.
Your request has been flagged as potentially automated. If you are human user receiving this message, please complete the CAPTCHA (bot test) below and click "Request Access". You may occassionally be asked to complete the CAPTCHA again, this is normal and part of our security measures.
unblock#handleSubmit">
Request Access
An official website of the United States government.
If you experiencing issues with the CAPTCHA or want to request a wider IP range, you can use the "Site Help" button found in the lower, right of this page to make a request.
×
IP Access Help
This contact form is only for IP Access help. Please do not provide confidential information or personal data.
* Your Name
* How can we help you?
Upload Attachment
* I am requesting technical help.
site-feedback#openModal" aria-label="Open site help form">
Site Help
Reproduced from Federal Register — FDA Advisory Committees · view original · public domain or open-licensed government work